Whalesbook Logo

Whalesbook

  • Home
  • About Us
  • Contact Us
  • News

Sterlite Technologies Navigates US Tariffs, Eyes Growth Amidst AI Boom

Tech

|

Updated on 07 Nov 2025, 05:50 am

Whalesbook Logo

Reviewed By

Simar Singh | Whalesbook News Team

Short Description:

Fiber optics manufacturer Sterlite Technologies Ltd (STL) is facing profitability pressure due to a 50% US tariff on its exports, impacting margins. However, the company anticipates this tariff may be reduced via a BTA soon. Despite this, STL sees strong medium-term growth prospects in the US and Europe, driven by telecom expansion and AI-led data center infrastructure, as evidenced by its order book nearly doubling in the first half of FY26. STL is also investing in R&D for next-generation products and expects improved capacity utilization and EBITDA margins.

▶

Stocks Mentioned:

Sterlite Technologies Ltd

Detailed Coverage:

Sterlite Technologies Ltd (STL) is currently experiencing a negative impact on its profitability due to a significant 50% tariff imposed on its fiber optic exports to the United States. This tariff has directly dented the company's margins. Managing Director Ankit Agarwal expressed hope that a Bilateral Trade Agreement (BTA) will be reached soon, potentially leading to a reduction in these tariffs during the current quarter, which would improve margins from the fourth quarter onwards.

Despite this short-term challenge, STL is observing robust demand and growth opportunities in its key markets, namely the US and Europe. The company's order book for the first half of FY26 has seen a substantial year-over-year increase, nearly doubling, primarily fueled by strong requirements from telecom operators and burgeoning data center clients. This growth is particularly significant in the US, which is projected to grow at a Compound Annual Growth Rate (CAGR) of 10-12% annually for the next three to four years. STL aims to capitalize on this by playing a role in the 'AI Boom' by supplying necessary infrastructure.

STL operates manufacturing facilities strategically located in India, Italy, and the US. The company plans to improve its capacity utilization to around 80% in the coming quarters, with the goal of pushing its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) margins towards 20%. To stay ahead of emerging data infrastructure needs, STL is investing over Rs 100 crore in Research and Development (R&D) this year. This investment is directed towards developing advanced optical products like multi-core and hollow-core fiber, high-capacity cables, and sophisticated connectivity solutions crucial for hyperscalers and data center companies requiring low-latency, high-bandwidth networks.

While the US remains STL's largest market for growth, the company also foresees significant momentum building in India's data center ecosystem over the next few years. STL is also involved in developing tactical cables for Indian defense and exploring new applications like fiber optics for drones, alongside supporting initiatives like BharatNet for rural connectivity.

In its latest financial results for the quarter ended September 2025, STL reported a net profit of Rs 4 crore, a notable improvement from a net loss of Rs 14 crore in the same period last year. Although revenue saw a slight decline of 4% to Rs 1,034 crore, EBITDA grew by 10.3% to Rs 129 crore, with the EBITDA margin improving to 12.5% from 10.9% year-on-year. The open order book at the end of Q2 stood at Rs 5,188 crore.

Impact: The US tariffs present a near-term headwind affecting STL's profitability. However, strong demand in the US and Europe for data infrastructure, driven by telecom and AI, coupled with R&D advancements and efforts to increase capacity utilization, are significant growth drivers. Successful reduction of tariffs and execution of large orders could lead to margin expansion and revenue growth, positively impacting the company's stock performance. The company's strategic diversification and investment in next-gen technology position it for future growth. Impact rating: 7/10

Definitions: BTA: Bilateral Trade Agreement. An agreement on trade between two countries. EBITDA: Earnings Before Interest, Taxes, Depreciation, and Amortization. A measure of a company's operating performance. CAGR: Compound Annual Growth Rate. The average annual growth rate of an investment over a specified period of time longer than one year. hyperscalers: Large cloud computing providers like Amazon Web Services, Microsoft Azure, and Google Cloud, which operate massive data centers. BharatNet: A government of India project to provide broadband internet access to all gram panchayats (village councils).


Healthcare/Biotech Sector

Divi's Laboratories Q3 Earnings Beat Estimates; Revenue Up 16%, Profit Soars 35%

Divi's Laboratories Q3 Earnings Beat Estimates; Revenue Up 16%, Profit Soars 35%

Sun Pharma Q2 FY26 Earnings Rise 8% Amid US Sales Dip; India & RoW Drive Growth

Sun Pharma Q2 FY26 Earnings Rise 8% Amid US Sales Dip; India & RoW Drive Growth

Achin Gupta to Lead Cipla as MD & Global CEO from April 2026, Focusing on Innovation Shift

Achin Gupta to Lead Cipla as MD & Global CEO from April 2026, Focusing on Innovation Shift

GSK Pharma Shares Tumble Over 3% as Q2 Revenue Falls Short of Expectations

GSK Pharma Shares Tumble Over 3% as Q2 Revenue Falls Short of Expectations

Eli Lilly's Mounjaro Becomes India's Top-Selling Drug by Value in October

Eli Lilly's Mounjaro Becomes India's Top-Selling Drug by Value in October

Divi's Laboratories Q3 Earnings Beat Estimates; Revenue Up 16%, Profit Soars 35%

Divi's Laboratories Q3 Earnings Beat Estimates; Revenue Up 16%, Profit Soars 35%

Sun Pharma Q2 FY26 Earnings Rise 8% Amid US Sales Dip; India & RoW Drive Growth

Sun Pharma Q2 FY26 Earnings Rise 8% Amid US Sales Dip; India & RoW Drive Growth

Achin Gupta to Lead Cipla as MD & Global CEO from April 2026, Focusing on Innovation Shift

Achin Gupta to Lead Cipla as MD & Global CEO from April 2026, Focusing on Innovation Shift

GSK Pharma Shares Tumble Over 3% as Q2 Revenue Falls Short of Expectations

GSK Pharma Shares Tumble Over 3% as Q2 Revenue Falls Short of Expectations

Eli Lilly's Mounjaro Becomes India's Top-Selling Drug by Value in October

Eli Lilly's Mounjaro Becomes India's Top-Selling Drug by Value in October


Personal Finance Sector

EPF 3.0 Overhaul: Simplified Withdrawal Rules Spark Backlash, Ministry Clarifies Intent

EPF 3.0 Overhaul: Simplified Withdrawal Rules Spark Backlash, Ministry Clarifies Intent

EPF 3.0 Overhaul: Simplified Withdrawal Rules Spark Backlash, Ministry Clarifies Intent

EPF 3.0 Overhaul: Simplified Withdrawal Rules Spark Backlash, Ministry Clarifies Intent